Our Principal, Pauli Wong, was invited to be one of the guest speakers at the “GBA Innovative MedTech Development Luncheon” on Wednesday (15 February) at HKSTP, sharing her insights on the unique IP challenges MedTech and healthcare innovations face in the GBA and China. The event was co-hosted by Society for Innovative Healthcare Hong Kong, Hong Kong College of Health Service Executives, GBA Medical Professional Study Tour, Doctors Think Tank Academy and CycloCorp.




我们的过去活动

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
阅读更多 >

From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

2025年10月21日
As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]
阅读更多 >

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]
阅读更多 >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
阅读更多 >
Top crossarrow-right